Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Current status of autologous stem cell transplantation for multiple myeloma
More than 30 years after its introduction, autologous stem cell transplantation (ASCT)
remains the standard of care for young patients with newly diagnosed multiple myeloma. Not …
remains the standard of care for young patients with newly diagnosed multiple myeloma. Not …
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the
treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice …
treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice …
Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis
Importance The role of high-dose therapy with melphalan followed by autologous stem cell
transplant (HDT/ASCT) in patients with multiple myeloma continues to be debated in the …
transplant (HDT/ASCT) in patients with multiple myeloma continues to be debated in the …
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
F Gay, M Engelhardt, E Terpos, R Wäsch… - …, 2017 - pmc.ncbi.nlm.nih.gov
Survival of myeloma patients has greatly improved with the use of autologous stem cell
transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs …
transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs …
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) …
Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …
settings has continued to improve survival outcomes for patients with Multiple Myeloma …
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for …
Multiple myeloma is the most common indication for high-dose chemotherapy with
autologous stem cell support (ASCT) in North America today. Stem cell procurement for …
autologous stem cell support (ASCT) in North America today. Stem cell procurement for …
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance …
HM Lokhorst, B van der Holt… - Blood, The Journal …, 2010 - ashpublications.org
The phase 3 trial HOVON-50 was designed to evaluate the effect of thalidomide during
induction treatment and as maintenance in patients with multiple myeloma who were …
induction treatment and as maintenance in patients with multiple myeloma who were …
[HTML][HTML] American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials …
In contrast to the upfront setting in which the role of high-dose therapy with autologous
hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with …
hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with …
[HTML][HTML] Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation
N Shah, N Callander, S Ganguly, Z Gul… - Biology of Blood and …, 2015 - Elsevier
Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past
decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered …
decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered …
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
PG Richardson, CS Mitsiades… - British journal of …, 2011 - Wiley Online Library
Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is induced in
response to cellular stress and stabilizes client proteins involved in cell cycle control and …
response to cellular stress and stabilizes client proteins involved in cell cycle control and …